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Abstract 35 
Background and Aims Induction of cross-reactive antibodies targeting conserved epitopes of the 36 
envelope proteins E1E2 is a key requirement for an HCV vaccine. Conserved epitopes like the viral 37 
CD81-binding site are targeted by rare broadly neutralizing antibodies. However, these viral segments are 38 
occluded by variable regions and glycans. We aimed to identify antigens exposing conserved epitopes and 39 
to characterize their immunogenicity. 40 
Methods We created HCV variants with mutated glycosylation sites and/or hypervariable region 1 41 
(HVR1). Exposure of the CD81 binding site and conserved epitopes was quantified by soluble CD81 and 42 
antibody interaction and neutralization assays. E2 or E1-E2 heterodimers with mutations causing epitope 43 
exposure were used to immunize mice. Vaccine-induced antibodies were examined and compared with 44 
patient-derived antibodies.  45 
Results Mutant viruses bound soluble CD81 and antibodies targeting the CD81 binding site with 46 
enhanced efficacy. Mice immunized with E2 or E1E2 heterodimers incorporating these modifications 47 
mounted strong, cross-binding, and non-interfering antibodies. E2-induced antibodies neutralized the 48 
autologous virus but they were not cross-neutralizing.  49 
Conclusions Viruses lacking the HVR1 and selected glycosylation sites expose the CD81 binding site and 50 
cross-neutralization antibody epitopes. Recombinant E2 proteins carrying these modifications induce 51 
strong cross-binding but not cross-neutralizing antibodies. 52 
Lay summary 53 
Conserved viral epitopes can be made considerably more accessible for binding of potently neutralizing 54 
antibodies by deletion of HVR1 and selected glycosylation sites. Recombinant E2 proteins carrying these 55 
mutations are unable to elicit cross-neutralizing antibodies suggesting that exposure of conserved epitopes 56 
is not sufficient to focus antibody responses on production of cross-neutralizing antibodies.  57 
Highlights 58 
 High resolution mapping of the impact of HVR1 and glycosylation sites on CD81 binding, 59 
antibody binding and virus neutralization 60 
 Viral mutants lacking HVR1 and selected glycosylation sites are functional and they expose the 61 
viral CD81 binding site and conserved cross-neutralization epitopes 62 
 E2 proteins with these mutations induce cross-binding and non-interfering antibodies in mice 63 
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Introduction 64 
Hepatitis C virus (HCV) is a global health burden affecting approximately 71 million people worldwide 65 
[1]. Infection often leads to chronic hepatitis, with the subsequent risk for liver cirrhosis and 66 
hepatocellular carcinoma. Persistent HCV infection is now curable with the introduction of direct-acting 67 
antivirals (DAAs). However, a prophylactic HCV vaccine is not available. Since viral re-infection is 68 
possible and as many HCV infected individuals are not diagnosed, a vaccine against HCV would facilitate 69 
global HCV eradication programs. 70 
The extreme diversity of HCV is a major obstacle for vaccine development [2]. The HCV E1E2 proteins 71 
are essential for viral cell entry, they bind the HCV receptor CD81 and they are targets for neutralizing 72 
antibodies. Hence, immunogens based on E1E2 represent one major branch of vaccine development [3, 4] 73 
and numerous approaches to induce E1E2-targeting broadly neutralizing antibodies (bNabs) have been 74 
explored [5]. For recombinant E1E2, the most advanced HCV subunit vaccine candidate, induction of 75 
robust cross-binding and cross-neutralizing antibody responses was observed in multiple animal models 76 
and in humans [4, 6, 7, 8].  77 
HCV has evolved mechanisms to evade humoral immune responses including high functional flexibility 78 
and variability of immunogenic portions of its envelope proteins [9]. The highest sequence variability 79 
occurs in the first 27 amino acids of the N-terminus of E2, which is referred to as the hypervariable region 80 
1 (HVR1), and which is dispensable for HCV infection in vitro [10, 11]. The HVR1 is immunogenic and 81 
most patients mount antibodies targeting this region [12]. However, these antibodies rapidly select 82 
resistant viral variants [13]. Deletion of the HVR1 renders HCV more susceptible to antibody 83 
neutralization, and it increases virus binding to soluble CD81, suggesting that this region occludes key 84 
neutralization epitopes and the viral CD81 binding site [10, 11]. HCV E1E2 heterodimers are also heavily 85 
glycosylated at multiple sites both within E1 and E2 and glycans modulate glycoprotein function and 86 
antibody neutralization [14, 15, 16]. Structural analyses of the E2 core domain show that the conserved 87 
CD81 binding site is surrounded by several glycosylation sites and that it overlaps with the epitopes of 88 
bNabs isolated from patients like for instance HC1 and HC11 [17, 18, 19, 20] (Fig. 1). Strikingly, in vitro 89 
HCV is unable to escape antibody pressure by HC-1 and HC-11 suggesting that immune responses 90 
targeting these epitopes may confer robust protection [21, 22]. 91 
We hypothesized that the HVR1 and protein glycosylation limits access to these conserved viral epitopes. 92 
In turn, immunogenicity of these epitopes may be low and antibodies targeting these viral regions may 93 
arise only very infrequently. To overcome this limitation and to focus immune responses to conserved 94 
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viral epitopes we combined targeted protein deglycosylation with deletion of HVR1 to create viruses and 95 
proteins with increased exposure of the crucial CD81 binding site and possibly superior immunogenicity. 96 
Results 97 
Inactivation of glycosylation sites and deletion of HVR1 increase exposure of conserved 98 
neutralization epitopes and the CD81 binding site 99 
To generate an improved HCV vaccine antigen, we aimed to increase the exposure of the CD81-binding 100 
site by combined mutation of the HVR1 and selected glycosylation sites. Jc1 reporter viruses expressing 101 
the J6 (GT2a) E1E2 proteins [23, 24] were constructed harboring N to A substitutions at glycosylation 102 
sites N417 (417) (numbering according to the H77 reference stain; J6 numbering in brackets), N423 (423), 103 
N448 (448), N532 (534) and N645 (649) (Fig. 1A). A previous report had shown that mutations at these 104 
residues still allowed viral entry of JFH1 and can therefore be studied and further evaluated in vitro [15]. 105 
Molecular modelling of the glycans associated with the HCV E2 core structure revealed that some were 106 
proximal to the CD81 binding site and conserved neutralization epitopes (Fig. 1B). Therefore, to further 107 
increase exposure of the CD81 binding site, we combined these mutations with the deletion of the HVR1. 108 
Fitness of mutant viruses was examined by transfection of Huh7-Lunet N#3 cells that do not express 109 
CD81 [25], and therefore do not permit reinfection of the cells. Replication of all viral mutants was 110 
comparable to wild type (WT) Jc1 (Fig. 1C). Huh-7.5 cells were inoculated with virus stocks after 111 
normalization to viral core protein that acts as a marker for virus particle release. In line with our previous 112 
report [10], deletion of HVR1 resulted in a 5-fold reduction of specific infectivity of Jc1 (Fig. 1D). 113 
Likewise, point mutations of individual glycosylation sites were well tolerated as specific infectivity was 114 
unaffected or at most reduced by ca. 5-fold. 115 
To examine the impact of these mutations on the exposure of conserved neutralization epitopes within the 116 
CD81 binding site, we used the soluble, large-extracellular loop of CD81 (CD81-LEL) and two potent 117 
bNabs (HC-1 and HC-11) that target the CD81 binding site [17, 18, 19, 20, 21], for precipitation of the 118 
indicated viral mutants (Fig. 2A and B). Deglycosylation of specific residues in the parental Jc1 virus 119 
slightly increased binding of HC-1 in particular for mutant N448A and N534A as is evidenced by 120 
enhanced core protein precipitation compared to Jc1, without being statistical significant (Fig. 2A). 121 
However, the deletion of HVR1 significantly enhanced precipitation by this antibody, which did not 122 
further increase by additional point mutations of glycosylation sites at indicated positions (Fig. 2A). 123 
Similar results were observed when the HC-11 antibody was used: mutation of individual glycosylation 124 
sites increased antibody binding (e.g. N423A, N448A). Deletion of HVR1 had the greatest effect, which 125 
was not further boosted by mutation of the glycosylation sites (Fig. 2B). Comparable results were obtained 126 
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when we used CD81-LEL for precipitation. In the context of parental Jc1, inactivation of individual 127 
glycosylation sites modestly increased precipitation (Fig. 2C). As may be expected from the available 128 
structural information (Fig. 1B) [17, 18], the effect was greatest for mutants N423A and N534A, as these 129 
glycosylation sites are directly adjacent to the CD81 binding site. Deletion of HVR1 had the greatest 130 
effect and precipitation of viruses lacking HVR1 was not further boosted by deglycosylation of specific 131 
residues.  132 
Deletion of HVR1 and glycosylation sites enhances virus neutralization  133 
To characterize the accessibility of HCV antibody epitopes, we performed neutralization assays with a 134 
panel of bNAbs (Fig. 3A and C and supplementary table 1). Moreover, we quantified virus neutralization 135 
by CD81-LEL (Fig. 3B and C and supplementary table 1). Dose dependence of neutralization for selected 136 
viruses is displayed in figure 3C. Radar plots indicating the inhibitory concentration 90% (IC90) of 137 
different antibodies or the CD81-LEL against parental HCV and all mutant viruses is displayed in figure 138 
3A and 3B. Each plot shows a specific virus and its sensitivity towards given antibodies (Fig. 3A), 139 
whereas figure panel 3B highlights the susceptibility of each virus to competition by CD81-LEL. In the 140 
context of parental Jc1, deletion of glycans at position N423 and N448 increased the susceptibility to all 141 
tested antibodies, whereas removal of glycosylation at residues N417, N534, and N649 had little effect 142 
(Fig. 3A upper panels). As expected, deletion of HVR1 enhanced neutralization by all antibodies tested. 143 
Combination of deletion of HVR1 with deletion of specific N-glycosylation sites modified neutralization 144 
by these antibodies, and the Jc1-ΔHVR1-N534A mutant exhibited a further enhanced susceptibility to 145 
neutralization by HC-1 and HC-11 (Fig. 3A and 3C). Removal of glycosylation at the N423, N534, and 146 
N417 site in the context of WT Jc1 enhanced inhibition of infection by CD81-LEL, whereas mutation of 147 
the N417 and N649 sites had no effect (Fig. 3B). Deletion of HVR1 increased neutralization by CD81-148 
LEL and this was further enhanced ca. 5-10-fold by addition of the N534 mutation. Therefore, combined 149 
deletion of HVR1 and inactivation of glycosylation site N534 enhanced antibody and CD81 binding to 150 
virus particles and it had the most drastic effect on neutralization by bNabs and soluble CD81.   151 
Next, we evaluated neutralization of Jc1, Jc1-N534A, Jc1-ΔHVR1and Jc1-ΔHVR1-N534A by sera from 152 
individuals chronically infected with HCV GT 1 and 2 (Fig. 4A-C). Similar to the results of neutralization 153 
with monoclonal antibodies and CD81-LEL (Fig. 3), the sera poorly neutralized Jc1. Neutralization was 154 
enhanced by elimination of the N534 site in Jc1, further boosted by deletion of HVR1, and it was maximal 155 
when the deletion of HVR1 was combined with the inactivation of the N534 glycosylation site with minor 156 
interpatient variation, independent of the patients` HCV genotype (Fig. 4A-C). Thus, combined deletion of 157 
HVR1 and inactivation of glycosylation site N534 enhanced antibody and CD81 binding to virus particles 158 
and it had the most drastic effect on neutralization by bNabs and soluble CD81 and patient sera. As these 159 
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viruses are infectious they present well-folded and functional viral envelope proteins that display 160 
conserved epitopes in a more accessible manner. Thus, envelope proteins carrying these modifications, 161 
particularly the deletion of HVR1 combined with the N534A mutation, may constitute good candidates for 162 
focusing antibody responses on conserved viral epitopes.  163 
Immunogenicity of recombinant E2 proteins with and without HVR1 and glycosylation 164 
To test this, we prepared soluble, truncated HCV J6 E2 protein variants in 293T cells and immunized 165 
BALB/c mice. These proteins have been previously reported to inhibit virus infection indicating that they 166 
are properly folded [26]. Supplementary figure 1 shows the immunization scheme. Briefly, animals 167 
received 30 µg of soluble E2 injected together with bis-(3',5')-cyclic dimeric adenosine monophosphate 168 
(c-di-AMP) as adjuvant and were boosted thrice with the same formulation. As control, animals were 169 
vaccinated with PBS and adjuvant only. We also used two vaccination series where we changed antigens 170 
in each boost in order to promote the stimulation of antibodies specific for the conserved epitopes. In 171 
sequence A animals were primed using WT J6 E2 (GT2a), followed by three boosters with E2HVR1 (J6 172 
GT2a derivative), E2HVR1/N534A (J6 GT2a derivative), and WT Con1 E2 (GT1b), respectively. In 173 
sequence B mice were primed with E2HVR1/N534A, followed by three booster immunizations with 174 
E2HVR1 (J6 GT2a derivative), WT Con1 (GT1b) E2, and WT J6 (GT2a) E2, respectively. Finally, to 175 
examine the relevance of global glycosylation for antigenicity, we vaccinated with WT J6 (GT2a) or with 176 
J6 (GT2a) E2HVR1 that had been deglycosylated by PNGaseF treatment prior to vaccination. 177 
The binding of vaccine-induced antibodies to 293T cell derived recombinant E2 proteins or E1-E2 178 
heterodimers from HCV infected cells was determined by ELISA (Fig. 5 and supplementary figure S2). 179 
Fig 5A shows end point titers of sera from vaccinated animals reacting with H77 (GT1a), Con1 (GT1b), 180 
J6 (GT2a) or J6HVR1 (GT2a) recombinant proteins. High binding titers across these GT1 and GT2 181 
antigens were observed in all vaccinated groups up to a maximal end point dilution approaching 10E6  182 
(Fig. 5A). Moreover, irrespectively of which protein was used for vaccination, most of these antibodies 183 
targeted binding sites outside of the HVR1, as end point titers were comparable between J6 (GT2a) and 184 
J6HVR1 (GT2a) ELISA antigens. Cross-binding activity to these recombinant E2 proteins was clearly 185 
enhanced for vaccination with E2HVR compared to wildtype recombinant E2 (Fig.5C left panel). 186 
Moreover, vaccination according to sequence A and B resulted in greater cross-binding to recombinant E2 187 
proteins. To evaluate the binding of these antibodies to heterodimeric E1-E2 protein complexes from 188 
different HCV strains, we used plates coated with galanthus nivalis lectin (GNA) to capture HCV E1E2 189 
complexes expressed in Huh-7.5 cells transfected with infectious HCVcc chimeras. Subsequently, these 190 
plates were incubated with sera from our vaccinated animals and end point binding titers were calculated 191 
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(Fig. 5B). In each group of vaccinated animals, anti-E2 antibodies binding to all examined E1-E2 protein 192 
complexes were detectable. Thus, each vaccination approach induced broadly cross-binding antibodies 193 
that recognize E2 proteins of all major HCV GTs. With exception of the vaccination with J6HVR-534 194 
E2 protein, however, all vaccination approaches induced antibodies with cross-binding activity to these 195 
E1-E2 heterodimers indistinguishable from the ones induced by parental J6 E2 (Fig. 5B and 5C right 196 
panel). Taken together, all vaccination approaches induced strong cross-binding antibodies to E2 and E1-197 
E2 heterodimers. Vaccination with different E2 proteins, most notably with E2HVR1, enhanced cross-198 
binding when judged by ELISAs involving recombinant E2. However, this difference was not detected 199 
when cross-binding was quantified with ELISAs based on E1-E2 heterodimers from cells replicating 200 
infectious virus.   201 
Evaluation of neutralizing activity of vaccine induced antibodies 202 
To examine autologous virus and virus cross-neutralizing responses we incubated Jc1 and GT5a reporter 203 
viruses, respectively, with increasing doses of purified IgG from vaccinated animals or from patient sera 204 
(Fig. 6A). The autologous virus Jc1 was neutralized by antibodies from the animals vaccinated with 205 
deglycosylated E2, with deglycosylated HVR1 or the series A antigen combinations. The strength of 206 
these autologous neutralizing antibody responses was at least as strong as the neutralization by polyclonal 207 
human antibodies collected from a panel of GT1, 2 and 3 chronically infected individuals. This correlated 208 
with comparable binding of patient-derived and vaccine-induced antibodies to recombinant E2 and virus 209 
particle associated E2, quantified by surface plasmon resonance and virus particle precipitation 210 
(supplementary figure S4). However, none of the vaccine-induced antibodies were able to cross-neutralize 211 
the GT5a reporter virus which was at least partially neutralized by the majority of patient derived 212 
antibodies.  213 
It has been reported that HCV induces antibodies that bind to E2 and that interfere with the activity of 214 
neutralizing antibodies, thereby masking vaccine-induced antibody neutralization [27, 28]. To explore 215 
whether our vaccine candidates induced such interfering antibodies, we used pooled polyclonal mouse 216 
IgGs from each vaccinated group and mixed them with polyclonal IgGs from a patient that displays strong 217 
neutralizing activity. The neutralization efficacy was not decreased by addition of IgG vaccinated mice, 218 
suggesting that the vaccines did not induce antibodies interfering with neutralization (Fig. 6B). 219 
The role of glycans and the HVR1 for immunogenicity was also assessed using protein from a different 220 
genotype (GT1a H77), as well as in the context of E1E2 heterodimers purified from CHO cell extracts. A 221 
detailed description of the purification procedure is provided in the materials and methods section and the 222 
quality control of the purification is given in supplementary figure S5A. The binding of E1E2 (WT), E1E2 223 
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(N417Q) and E1E2 (N532Q) antigens to CD81-LEL was examined by ELISA and revealed enhanced 224 
binding for E1E2 (N532Q) compared to parental E1E2 and the N417Q mutant (Fig. 7A and 225 
supplementary figure S5B). These GT1a antigens were used to immunize mice resulting in the induction 226 
of E2 specific antibody responses comparable between all groups (Fig. 7B). As shown in figure 7C all 227 
three vaccine candidates induced antibodies competing with binding of the  known monoclonal antibodies 228 
AR3B, 1:7, HC33.4 and AP33 as assessed by a competition assay. Finally, we used GT1a H77 HCVpp 229 
assays to examine neutralization efficacy of vaccine induced antibodies. Each vaccine candidate induced 230 
HCVpp neutralizing antibodies whereby no significant differences between the vaccine candidates were 231 
observed (Fig. 7D).  232 
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Discussion 233 
Here we provide a high resolution map of viral determinants that govern exposure of the CD81 binding 234 
site and of conserved neutralization epitopes. We show that these changes are well tolerated indicating 235 
that they do not abrogate the functioning of E1/E2. The most global change in antibody 236 
binding/neutralization and CD81 binding/neutralization was accomplished by deletion of HVR1 combined 237 
with inactivation of glycosylation site 534. Thus, we chose this combined modification for vaccination 238 
approaches involving recombinant proteins. To rule out strain-specific differences between immunogens, 239 
we created these variants in the background of J6 (GT2a) E2 and in the context of the H77 (GT1a) strain. 240 
We prepared H77 E1E2 heterodimers from CHO cell extracts and recombinant E2 protein secreted from 241 
293T cells to examine the importance of producer cells and the relevance of E1. To globally assess the 242 
relevance of glycosylation in our vaccine candidates we also examined the immunogenicity of 293T cell-243 
derived proteins that had been enzymatically deglycosylated prior to vaccination. Finally, we included a 244 
vaccination protocol involving variable immunogens and in each case at least one immunogen from an 245 
alternative viral GT.   246 
All vaccination approaches induced robust cross-binding antibody responses as determined by ELISA 247 
assays involving recombinant proteins or cell extracts expressing E1-E2 heterodimers from all major HCV 248 
GTs (Fig. 5). Vaccination with E1-E2 heterodimers induced antibodies that competed with the binding of 249 
previously described bNAbs AR3B, 1:7, HC33.4 and AP33 and we detected virus neutralization in 250 
HCVpp assays (Fig. 7). However, inactivation of N417 or N532 glycosylation sites in the context of H77 251 
E1E2 heterodimers did not grossly affect these responses although the mutation N532Q mediated 252 
increased binding of the recombinant E1E2 complex to CD81. Among vaccinations with 293T-derived E2 253 
proteins immunization with J6-E2HVR1 and the two immunization series A and B mounted superior 254 
cross-binding antibodies compared with J6-E2 and the other examined approaches. However, this was 255 
only detected when recombinant E2 proteins from 293T cells were used as ELISA antigens and not when 256 
E1-E2 heterodimers partially purified from HCV replicating cells were employed. Thus, some of our E2-257 
protein based vaccination approaches successfully improved production of cross-binding antibodies to the 258 
recombinant immunogens but not to the E1-E2 heterodimer expressed in infected cells. Thus, apparently 259 
there are structural differences between these proteins and E1-E2 heterodimers. These differences could 260 
impact on vaccine efficacy and they should be considered when standardizing tests between laboratories 261 
and when estimating cross-binding between different studies. It is also possible that such structural 262 
differences were responsible that vaccination with 293T-derived E2 proteins triggered only modest 263 
autologous neutralizing antibodies and no cross-neutralization. It has been shown that purified, UV-264 
inactivated HCVcc particles induce cross-neutralizing antibodies in mice and non-human primates [29, 265 
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30]. Thus, it will be interesting to explore if vaccination with the HCVcc variants characterized here 266 
induces a focused and enhanced neutralizing antibody response. 267 
It is surprising that vaccination with E2 from 293T cells induced very robust, cross-binding antibodies 268 
that, however, did not cross-neutralize. One possible explanation was that these immunogens induced 269 
antibodies that interfere with cross-neutralization as has been described previously [27, 28]. However, the 270 
vaccine induced antibodies did not interfere with cross-neutralization of HCV patient derived polyclonal 271 
antibodies (Fig. 6). Thus, we believe that the 293T-derived E2 vaccines examined here efficiently induced 272 
antibodies that target conserved binding epitopes, but that targeting these epitopes is not cross-273 
neutralizing. It is possible that this reflects in part a species-specific limitation of immunogenicity of 274 
recombinant E2 proteins in mice as recent results by other groups and us suggest that anti-HCV 275 
neutralizing antibody responses are more readily induced in guinea pigs [31, 32]. Although neutralizing 276 
antibodies were elicited, those were primarily strain-specific, thus explaining the neutralization of 277 
autologous Jc1 particles. Notably, the conserved CD81 binding site seems to be structurally highly 278 
flexible, and it was proposed that this flexibility may favor induction of non-neutralizing antibodies [33]. 279 
In line with this, it is possible that the recombinant E2 proteins used here preferentially adopt a 280 
conformation that induces binding, but non-neutralizing antibodies and that the conformation inducing 281 
neutralizing antibodies may be under represented in these recombinant proteins. Thus, epitope exposure 282 
alone may be insufficient and should be complemented by vaccine design aiming at rigidifying this 283 
region. 284 
The lack of robust immunocompetent animal models permissive for HCV makes it hard to assess if the 285 
quantity and quality of vaccine-induced immunity is sufficient to confer protection. Thus, it is difficult to 286 
predict to which extent antibody responses induced by current vaccination approaches, including the ones 287 
presented here, contribute to protection. In vivo, antibody functions independent of direct virus particle 288 
neutralization could facilitate protection. For instance antibody dependent cytotoxicity (ADCC) may 289 
contribute to clearance of HCV infected cells. In this regard, binding, but non-neutralizing antibodies may 290 
contribute to HCV protection, as has been recently reported for an HIV infection in vivo [34]. Therefore, 291 
development of vaccination approaches inducing strong T cell responses as well as nNAbs and bNAbs and 292 
involving all antibody effector functions is likely of key importance for induction of robust protection.    293 
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Materials and Methods 306 
Plasmid constructs  307 
The renilla-luciferase harboring Jc1 [23] and Jc1-ΔHVR1 [10] viral cDNA clones with or without alanine 308 
substitutions within N-linked glycosylation-sites of E2 (N417A, N423A, N448A, N534A and N649A) 309 
were constructed by standard PCR-based techniques and verified by sequencing. 310 
HCVcc neutralization assay 311 
For inhibition of HCV infection, 200 μl of a Huh7.5 cell suspension (5 × 104 cells per ml) was seeded into 312 
each well of a 96-well plate 24 h prior to inoculation. Luciferase reporter viruses were mixed with serial 313 
dilutions of indicated serum/antibody concentrations and pre incubated for 1 h. This mixture was used to 314 
inoculate cells for 4 h in triplicates per dilution. Thereafter, 170 µl of DMEM was added onto the cells. 315 
Viral infection was determined 48 or 72 h after infection by removing the supernatant and lysing of the 316 
cells by addition of passive lysis buffer or water and measurement of RLU using a 96-well plate reader 317 
(Berthold). 318 
HCV pseudotyped viruses (HCVpp) neutralization assay  319 
HCV pseudotyped viruses (HCVpp) expressing a luciferase reporter were generated as described [35]. For 320 
neutralization assays, Huh7.5 cells were plated on poly-lysine coated 96-well plates 1 day prior to 321 
infection. HCVpp were diluted 1:10 and premixed with heat inactivated diluted sera (1:100) for 1 h at 322 
37°C followed by addition to Huh 7.5 cells. Six hours post-infection, the antibody-virus inoculum was 323 
replaced with fresh culture medium. Cells were processed 48 h post-infection using the Bright-glo 324 
luciferase assay system (Promega, Madison, WI, USA). Luminescence was measured using an Enspire 325 
plate reader (Perkin-Elmer,Waltham, MA, USA). The neutralization activity was calculated using the 326 
following formula: % neutralization = (pre-post)/pre × 100 where pre/post represent the luciferase activity 327 
done after incubating with either the pre- or post-vaccination sera. 328 
Molecular modeling  329 
Modelling of the glycosylated core structure (PDB 4MWF) was performed using Glycoprotein Builder 330 
(www.glycam.org). Glycans are depicted as wireframes; protein as a surface. The predicted CD81 binding 331 
site and mAb HC1/HC11 epitopes (highlighted in green) were annotated using UCSF Chimera 332 
(www.cgl.ucsf.edu/chimera) using a space fill model. Other amino acid side chains were coloured by 333 
hydrophobicity (red = hydrophobic; blue = hydrophilic as determined by the Kyte-Doolittle scale).  334 
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Figure Legends 433 
 434 
Figure 1: Schematic and structure of HCV E2 and characterization of mutant viruses. (A) N-linked 435 
glycosylation sites (NGS) in the HCV E2 ectodomain are indicated by inverted open triangles. For 436 
positional referencing, a graphic chart of the E2 protein is located directly below, with two hypervariable 437 
regions and the intergenic variable region (HVR1, HVR2 and igVR) highlighted, and the stem region of 438 
E2 marked in light grey. All numbering is relative to the full-length ORF position in the H77 (GT1a) 439 
reference strain (accession number NC_004102) while numbers in brackets indicate the homologous 440 
position in the J6 (GT2a) E2 ectodomain. The HVR1 region and glycan sites, which were deleted, are 441 
indicated in red. Zoomed in region highlights the viral CD81 binding site with key contact residues 442 
displayed in blue [36, 37]. Amino acid important for binding of bNAbs HC1, HC11, and HC84-like 443 
antibodies are highlighted with colored inverted triangles (pink, HC1; green HC11, orange HC84-series). 444 
** indicates indels responsible for length differences between H77 (GT1a) and J6 E2 (GT2a). Note that 445 
HC84.20 also binds to Y613 and W616 and HC84.22 also binds to W616. (B) Structural modelling of the 446 
E2 core domain with the CD81, HC1 and HC11 binding sites highlighted in green. Glycosylation was 447 
modelled using Glycoprotein Builder and are shown and numbered according to the H77 (GT1a) reference 448 
strain. The E2 protein is colored by hydrophobicity of aa side chains (red and blue represent hydrophobic 449 
and hydrophilic residues, respectively) and green shows antibody or CD81 contact residues. (C) 450 
Replication of mutant viruses with alanine substitutions at indicated positions with or without deletion of 451 
the HVR1 within the E2 protein. Viral replication was determined by renilla-luciferase activity of cell 452 
lysates 48 h after transfection (n=3, duplicates each; SD). (D) Specific infectivity of particles. Released 453 
virus was normalized to equal amounts of core and was used to infect Huh-7.5 cells. Infection is displayed 454 
as RLU per well (n=3, measured in triplicates each; SD). The dotted line depicts the background of the 455 
assay as determined by measurements of uninfected cell lysates.  456 
Figure 2: Precipitation of mutant viruses with monoclonal antibodies and with GST-CD81-LEL. 457 
Mutant viruses were normalized to equal amounts of core and incubated with either HC-1 (A), HC-11 (B) 458 
or with GST-C81-LEL (C), respectively. Virus-antibody or virus-CD81-LEL-GST complexes were 459 
precipitated by addition of protein G or glutathione coated beads. Viral core protein was determined to 460 
measure bound viral particles. Data are expressed as fold over control (antibody RO4 or GST) and 461 
compared to WT virus (n=4, ANOVA, Friedman, Dunn’s multiple comparison, p<0.05 (*), p<0.01 (**), 462 
p<0.001 (***)). Symbols represent individual IPs. 463 
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Figure 3: Neutralization of Jc1 and mutant viruses by antibodies or by receptor competition with 464 
GST-CD81LEL. Viruses were incubated with serial dilutions of given antibodies (A) or GST-CD81-LEL 465 
(B) and infection efficiency was quantified by luciferase assays. Selected dose-response curves are plotted 466 
in panel (C). Radar plots in (A) highlight IC90 values (µg/ml) for antibody neutralization, and IC90 values 467 
of GST-CD81-LEL receptor competition in panel (B), respectively. The IC90 values were calculated using 468 
non-linear regression method on graph pad version 6. Abbreviations: RLU, Relative light units.  469 
Figure 4: Neutralization of viruses by GT1 and GT2 patient sera. Indicated viruses were mixed with 470 
serial dilutions of sera of uninfected (A, #1-3), GT1 (B, #1-3) or GT2 infected (C, #1-3) individuals. 471 
Infection efficiency was quantified by inoculation of Huh-7.5 cells and subsequent luciferase assays. It is 472 
plotted relative to control infections in the absence of human serum. Means ± SD (n=2(A/B/C #1-2) or 473 
3(A/B/C #3)). 474 
Figure 5: Cross-binding of vaccine-induced antibodies to HCV GT1 to 6 glycoproteins.  (A) 475 
Recombinant E2 proteins (2 µg/ml) from different HCV GTs were immobilized on ELISA plates. (B) 476 
Alternatively, E1-E2 heterodimers prepared from virus transfected cells were used to determine antibody 477 
cross binding. Plates were incubated with serial dilutions of mouse sera from vaccinated and mock treated 478 
animals, and bound antibodies were detected with a secondary anti-mouse antibody coupled to horseradish 479 
peroxidase (HRP). The background detected upon incubation with sera from mock vaccinated animals 480 
was subtracted and the end point binding titers were calculated based on the median effect method as 481 
described in the materials and methods section. Raw data are provided in the supplementary figure 2A and 482 
B. (C) Antibody cross-binding expressed relative to vaccination with the parental J6-E2 protein and 483 
measured by ELISAs using recombinant E2 (left panel) or E1-E2 heterodimers extracted from cells with 484 
infectious HCV (right panel). Horizontal bars represent the median value of cross binding relative to the 485 
wildtype J6-E2 vaccination. 486 
Figure 6: Quantification of vaccine-induced neutralizing antibody responses. (A) Neutralization of 487 
autologous Jc1 and of heterologous GT5A reporter virus by vaccine induced mouse antibodies and human 488 
antibodies from HCV patients. Viruses were incubated with given doses of antibodies and infection 489 
efficiency was determined and expressed relative to infections conducted in the absence of antibodies. 490 
Means ± SD of three technical replicates are shown. (B) Influence of vaccine-induced mouse IgG on 491 
neutralization by human neutralizing antibodies. Purified mouse IgGs (100µg/ml; pooled from all animals 492 
in one group) were mixed with human IgG (10µg/ml) from an HCV patient, pre-incubated with GT5a 493 
reporter virus for 1h, and then used to inoculate Huh-7.5 cells. Infection efficiency was determined as 494 
above and is expressed relative to infections conducted in the absence of any IgGs. Means ± SD (n=3). 495 
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Figure 7: Vaccination with E1E2 heterodimers with or without glycosylation site mutation induces 496 
comparable neutralizing antibody responses. (A) Effect of N-glycosylation mutations on E1E2 497 
interaction with CD81-LEL. Purified WT or N-glycosylation mutant (N417Q and N532Q) E1E2 proteins 498 
(25, 50 and 100 ng) were added to CD81-LEL coated wells or BSA coated wells (single 100 ng E1E2 499 
dose) as a negative control. Bound E1E2 antigens were detected by anti-E2 (H53) mAb. Values are shown 500 
as a percentage of WT E1E2 binding at the highest dose tested (100 ng). (*) Designates p<0.05 respective 501 
to WT (100 ng) by One way ANOVA; Tukey post-hoc test. (B) HCV E2 binding antibodies induced by 502 
vaccination. WT recombinant E2 (384-661) H77c antigens were coated to ELISA plates in triplicate and 503 
probed with post-vaccinated mice sera. Binding of E2-specific antibodies from WT, N417Q, and N532Q 504 
(1000, 2000, 4000-fold dilutions) vaccinated animals compared to control (C) sera (1000-fold dilution) 505 
were detected by anti-mouse HRP conjugated secondary antibody and peroxidase substrate. The OD450-506 
570 nm values (mean and SEM) plotted vs serum dilution. Shown is one representative of three 507 
independent experiments. (C) Competition of mice antisera with HCV cross-neutralizing monoclonal 508 
antibodies (mAb) to E1E2. Microtiter wells containing GNA-purified E1E2 H77c were incubated with 509 
diluted terminal antiserum (1:100) from control (C) or E1E2 (WT, N417Q or N532Q antigen) vaccinated 510 
mice. After washing, plates were incubated with anti-HCV mAbs. Bound AR3B, 1:7 and HC33.4 were 511 
detected with anti-human alkaline phosphatase-conjugated secondary antibody and biotin-AP33 detected 512 
using neutravidin-alkaline phosphatase. The percentages of mAb binding were calculated relative to the 513 
amount of mAb bound in the absence of antiserum. Shown are mean values for each group ± range from 514 
three independent experiments. (*) designates p<0.05 respective to the control group by One way 515 
ANOVA; Tukey post-hoc test. (D) Comparison of the HCVpp (H77) neutralization response from WT 516 
and N-glycosylation mutant E1E2 vaccinated mice. Neutralization assay using homologous HCVpp H77 517 
(1a) were performed using pre- and post-vaccinated sera (1:100) and the group means with SEMs plotted 518 
from representatives of three independent experiments. Positive control: Anti-CD81 mAb [1 μg/ml]).  519 
Abbreviations: OD, optical density. 520 
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*Graphical Abstract
Highlights 
 High resolution mapping of the impact of HVR1 and glycosylation sites on CD81 binding, 
antibody binding and virus neutralization 
 Viral mutants lacking HVR1 and selected glycosylation sites are functional and they expose 
the viral CD81 binding site and conserved cross-neutralization epitopes 
 E2 proteins with these mutations induce cross-binding and non-interfering antibodies in mice 
 
*Highlights
